CYNTHIA N. OLIVER,ERICA SHANE,BENJAMIN S. ISSAACS FORMATECH, INC.,CHRISTIAN B. ALLAN,STEPHEN CHANG
申请号：
PT10010453
公开号：
PT2327421T
申请日:
2003.06.16
申请国别(地区):
PT
年份:
2018
代理人:
摘要：
The present invention provides liquid formulations of SYNAGIS ® or an antigen binding fragment thereof that immunospecifically bind to a respiratory syncytial virus (RSV) antigen, which formulations exhibit stability, low to undetectable levels of aggregation, and very little to no loss of the biological activities of SYNAGIS ® or an antigen-binding fragment thereof, even during long periods of storage. In particular, the present invention provides liquid formulations of SYNAGIS ® or an antigen-binding fragment thereof which immunospecifically binds to a RSV antigen, which formulations are substantially free of surfactant, inorganic salts, and/or other common excipients. Furthermore, the invention provides methods of preventing, treating or ameliorating symptoms associated with RSV infection utilizing liquid formulations of the present invention.
